Preventive Cancer Vaccines Targeting Predictable Neoantigen Peptides in Lynch Syndrome | Research

The takeaway

Lynch syndrome — the most common inherited cancer predisposition — produces predictable frameshift peptide neoantigens that could be targeted by preventive vaccines, with RNA-based platforms showing the strongest potential.

Predictable neoantigens
Unlike most cancers with random mutations, Lynch syndrome produces a defined, predictable set of frameshift peptide neoantigens — making it uniquely suited for a universal preventive cancer vaccine.

What the researchers found

DNA mismatch repair-deficient cancers produce a defined and predictable set of frameshift peptide neoantigens due to insertion/deletion mutations in coding microsatellites. These neoantigens are foreign to the immune system and can elicit strong CD8+ cytotoxic T cell responses.

Evidence shows pre-existing immune surveillance against these neoantigens exists in Lynch syndrome carriers, suggesting the immune system already partially recognizes pre-cancerous cells. Three mechanisms of immune evasion allow cancers to escape this surveillance. A preventive vaccine could strengthen immune surveillance before evasion occurs. The review evaluates antigen selection and delivery strategies, concluding that RNA vaccines offer the most robust potential for immunoprevention.

Why it matters

Preventing cancer is fundamentally better than treating it. Lynch syndrome affects an estimated 1 in 279 people and carries up to 80% lifetime cancer risk. Because the neoantigens are predictable (unlike in most cancers), a single vaccine formulation could potentially protect all carriers — making this one of the most feasible preventive cancer vaccine approaches. Success here could establish a model for preventing other genetically defined cancers.

How the study worked

This is a comprehensive review article examining the pathogenesis of DNA mismatch repair-deficient cancers, evidence for immune surveillance, mechanisms of immune evasion, and the rationale for preventive vaccination. The authors review both preclinical studies and early clinical experience with frameshift peptide neoantigen-based vaccines, and evaluate antigen selection and delivery strategies.

What this study cannot tell us

This is a review article presenting no new experimental data. The preventive vaccine concept, while scientifically compelling, has not been proven in large-scale human trials. Pre-existing immune surveillance in carriers suggests some natural protection already exists, and it's unclear how much additional benefit a vaccine would provide. The optimal antigen combination and delivery platform remain to be determined. Long-term safety of repeated neoantigen vaccination in healthy carriers needs evaluation.

How to read the evidence

This is a comprehensive review article published in a leading immunotherapy journal. While it synthesizes compelling preclinical and early clinical evidence, the preventive vaccine concept itself remains unproven in large-scale human trials.

When this study was published

Published in 2022, this review captures the state of the field as preventive cancer vaccine research has gained momentum, particularly with advances in RNA vaccine technology demonstrated during the COVID-19 pandemic.

The bigger picture

Cancer prevention vaccines represent a paradigm shift from treatment to prevention. While therapeutic cancer vaccines have had limited success due to tumor immune evasion, preventive vaccines — given before cancer develops — could intervene at a stage when the immune system still has the upper hand. Lynch syndrome is considered the ideal test case because of its defined genetics, identifiable at-risk population, and predictable neoantigens. Success could catalyze preventive vaccine development for other hereditary cancer syndromes.

Questions still open

How many frameshift peptide neoantigens need to be included in a preventive vaccine to provide comprehensive protection against Lynch syndrome cancers?
Could a preventive cancer vaccine for Lynch syndrome reduce the need for frequent colonoscopy surveillance?
Would the same frameshift peptide targets work for sporadic mismatch repair-deficient cancers that are not part of Lynch syndrome?

Common questions

Could a vaccine prevent cancer in people with Lynch syndrome?

It's a realistic possibility. Lynch syndrome causes predictable mutations that produce abnormal proteins the immune system can learn to recognize. A vaccine could train immune cells to destroy cells carrying these mutations before they become cancerous. RNA-based vaccines are considered the most promising delivery method, and early clinical studies are underway.

What makes Lynch syndrome cancer different from other cancers for vaccine development?

Most cancers have random, unpredictable mutations unique to each patient. Lynch syndrome cancers produce the same set of predictable frameshift mutations across patients because they all have the same underlying DNA repair defect. This means a single vaccine formulation could work for all carriers — a major advantage over personalized cancer vaccines.

Read the original research

Vaccines for immunoprevention of DNA mismatch repair deficient cancers.

Journal for immunotherapy of cancer, 10(6)

View on PubMed ↗Publisher’s paper ↗

Citation

Hernandez-Sanchez, Alejandro; Grossman, Mark; Yeung, Kevin; Sei, Shizuko S; Lipkin, Steven; Kloor, Matthias. (2022). Vaccines for immunoprevention of DNA mismatch repair deficient cancers.. Journal for immunotherapy of cancer, 10(6). https://doi.org/10.1136/jitc-2021-004416